Cannabis-induced psychosis affects thousands annually, with relapse rates approaching 50% despite treatment. Finding the minimal effective antipsychotic dose could reduce debilitating side effects while maintaining protection against devastating psychotic episodes that can permanently alter life trajectories.
Swedish researchers tracked 1,772 individuals diagnosed with cannabis-induced psychosis between 2006-2021, analyzing hospitalization rates across different antipsychotic medications and dosing levels. Using sophisticated within-individual modeling, they examined three dose categories: low (<0.6 daily defined doses), moderate (0.6-1.4), and high (≥1.4). Clozapine at moderate doses and antipsychotic polytherapy consistently reduced hospitalization risk by 35-46% across all dose ranges, with hazard ratios of 0.54-0.65.
This nationwide analysis provides crucial dosing guidance for a particularly vulnerable population. Cannabis-induced psychosis typically affects younger individuals during critical life stages, making effective prevention essential. The finding that moderate clozapine doses match higher-dose effectiveness suggests clinicians can minimize metabolic and neurological side effects without compromising protection. However, the study's observational design cannot establish causation, and the Swedish healthcare system's unique characteristics may limit global applicability. Additionally, the analysis doesn't account for cannabis use patterns during treatment, which could significantly influence outcomes. While promising, these findings require validation in randomized controlled trials before reshaping clinical practice. The research nonetheless represents meaningful progress toward precision psychiatry for substance-induced psychotic disorders.